Q3 EPS Estimate for Abeona Therapeutics Increased by Analyst

Abeona Therapeutics Inc. (NASDAQ:ABEO) – Equities research analysts at HC Wainwright increased their Q3 2026 earnings per share estimates for shares of Abeona Therapeutics in a research report issued to clients and investors on Monday, August 24th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will earn ($0.25) per share for the quarter, up from their prior estimate of ($0.26). HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for Abeona Therapeutics’ Q4 2026 earnings at ($0.24) EPS, FY2026 earnings at ($1.15) EPS, Q1 2027 earnings at ($0.20) EPS and FY2027 earnings at ($0.49) EPS.

Several other research firms have also recently commented on ABEO. Wall Street Zen upgraded Abeona Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st. Weiss Ratings downgraded shares of Abeona Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, August 17th. Finally, Oppenheimer reissued an “outperform” rating and issued a $21.00 price objective (down from $22.00) on shares of Abeona Therapeutics in a research report on Friday, August 14th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $19.33.

Abeona Therapeutics Stock Up 2.5%

NASDAQ:ABEO opened at $6.21 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.40 and a current ratio of 6.63. The company has a market cap of $355.09 million, a PE ratio of -5.70 and a beta of 1.35. Abeona Therapeutics has a 52-week low of $4.00 and a 52-week high of $7.65. The stock has a 50-day simple moving average of $6.40 and a 200 day simple moving average of $5.62.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.12). The firm had revenue of $11.38 million during the quarter, compared to the consensus estimate of $12.24 million.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. AIGH Capital Management LLC lifted its holdings in Abeona Therapeutics by 55.0% during the 1st quarter. AIGH Capital Management LLC now owns 3,100,000 shares of the biopharmaceutical company’s stock valued at $13,888,000 after purchasing an additional 1,100,000 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its position in shares of Abeona Therapeutics by 14.2% in the second quarter. Adage Capital Partners GP L.L.C. now owns 3,072,985 shares of the biopharmaceutical company’s stock valued at $17,455,000 after purchasing an additional 381,357 shares during the period. Vanguard Group Inc. lifted its stake in shares of Abeona Therapeutics by 3.8% during the 3rd quarter. Vanguard Group Inc. now owns 2,602,901 shares of the biopharmaceutical company’s stock worth $13,743,000 after buying an additional 95,878 shares during the last quarter. AWM Investment Company Inc. bought a new stake in shares of Abeona Therapeutics during the 2nd quarter worth about $9,184,000. Finally, Geode Capital Management LLC grew its stake in Abeona Therapeutics by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 1,137,127 shares of the biopharmaceutical company’s stock valued at $5,994,000 after buying an additional 9,996 shares during the last quarter. 80.56% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Abeona Therapeutics

In other Abeona Therapeutics news, SVP Brendan M. O’malley sold 12,050 shares of the company’s stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $6.96, for a total value of $83,868.00. Following the sale, the senior vice president owned 427,953 shares in the company, valued at $2,978,552.88. This represents a 2.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Christine Berni Silverstein sold 18,160 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $5.71, for a total value of $103,693.60. Following the completion of the sale, the director directly owned 119,562 shares of the company’s stock, valued at approximately $682,699.02. The trade was a 13.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 274,578 shares of company stock worth $1,674,433 over the last ninety days. Company insiders own 7.10% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics is a clinical?stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life?threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non?viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV?based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.